Business
InvestmentPitch Media Video Discusses Rakovina Therapeutics' Partnership with St. Baldrick's Foundation to Research and Develop New Treatments for Childhood Bone Cancer - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2021) -  Rakovina Therapeutic...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"InvestmentPitch Media Video Discusses Rakovina Therapeutics' Partnership with St. Baldrick's Foundation to Research and Develop New Treatments for Childhood Bone Cancer - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - November 17, 2021) -  Rakovina Therapeutics Inc. (TSXV: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, has been selected to join a three year research program funded by the St. Baldrick's Foundation Martha's BEST Grant for All. The US$975,000, or CDN$1,297,000, research program is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.For more information, please view the InvestmentPitch Media \"video\" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Rakovina\" in the search box.Cannot view this video? Visit:https://www.youtube.com/watch?v=5IKsKz4pXbsMartha's Better Ewing Sarcoma Treatment (BEST) Grant for All is a St. Baldrick's grant named in honor of a 19-year-old girl who has fought the disease for over 6 years, after first being diagnosed with Ewing sarcoma in 2015, at the age of 13. Martha was happy to have her name associated with the grant but insisted on the \"for All\" to recognize the many other children diagnosed with Ewing sarcoma every year. Having faced numerous relapses over the years, Martha is undeterred and continues her battle against Ewing Sarcoma. Continuing to put her faith behind the cancer research community, Martha plans to enroll in a clinical trial at Boston Children's Hospital in December 2021.Prof. Mads Daugaard, Rakovina Therapeutics president and chief scientific officer, is a principal researcher in the project along with Prof. Poul Sorensen at the University of British Columbia. Rakovina Therapeutics recently presented preclinical data at peer reviewed scientific meetings demonstrating the potential of Rakovina Therapeutics' kt-3000 series drug candidates against treatment-resistant cancer cell lines, including Ewing sarcoma.Prof. Mads Daugaard, Rakovina's President and Chief Scientific Officer, stated: \"Our data demonstrate that kt-3000 series compounds are equal or more effective against Ew...